Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
Via ACCESSWIRE
News headline image
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
Via ACCESSWIRE
News headline image
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
Via ACCESSWIRE
News headline image
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Via ACCESSWIRE
News headline image
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
Via ACCESSWIRE
News headline image
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023
Via ACCESSWIRE
News headline image
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
Via ACCESSWIRE
News headline image
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
Via ACCESSWIRE
News headline image
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles
Via ACCESSWIRE
News headline image
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo
Via ACCESSWIRE
News headline image
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics’ SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model
Via ACCESSWIRE
News headline image
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties
Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet 
Via Spotlight Growth
News headline image
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Via ACCESSWIRE
News headline image
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
Via ACCESSWIRE
News headline image
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
Via ACCESSWIRE
News headline image
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
From Altamira Therapeutics Ltd
Via GlobeNewswire
News headline image
Altamira Therapeutics Provides Year-End 2022 Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.